#$%^&*AU2012203931A120120726.pdf#####ABSTRACT This invention relates to a novel use of IL-I P-ligand/IL-1 receptor disrupting compounds (herein referred to as "IL-I beta Compounds") such as small molecular compounds disrupting IL-1 0 ligand - IL-I receptor interaction, IL-1 0 antibodies or IL- receptor antibodies, e.g. IL-1 p binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1 P binding compounds or IL-I receptor binding compounds, and/or RNA compounds decreasing either IL-1 0 ligands or IL-I receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
